US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 23:10:54 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Company wins court ruling to continue development of Michigan factory serving EV industry
Next:Israeli army says it kills over 130 militants in E. Rafah
You may also like
- Flight attendant reveals why plane passengers should NEVER fall asleep before take off
- Egyptian, French FMs discuss Gaza developments, truce proposal
- UN General Assembly to resume emergency special session on Mideast
- Rwanda's rebirth
- Trump film shocks Cannes as former US President is depicted 'raping' his then
- Emerging trends for upcoming May Day holiday
- PSG defender Hernandez needs surgery after rupturing ACL and set to miss Euro 2024
- Wisconsin tries to regain supremacy in the trenches under its 4th O
- Judge blocks Biden administration from enforcing new gun sales background check rule in Texas